Our internal groups innovate in the following product lines: Transcatheter Aortic Valve Replacement therapies leads the industry in innovation for less-invasive aortic heart valve replacement therapies that improve patient outcomes Surgical Structural Heart is extending its leadership position as the partner of choice for surgeons and their teams; focusing on active patients, complex cases and aortic insufficiency; and expanding therapies to broader populations Critical Care invests to strengthen its core hemodynamic portfolio, helping clinicians make proactive clinical decisions that play an important role in enhancing patient recovery Transcatheter Mitral and Tricuspid Therapies aims to transform the care of patients with mitral and tricuspid regurgitation though an advanced toolbox of new therapies.